Syneos Health (Nasdaq:SYNH) - Aktienkurs, Nachrichten und Analyse

SYNH Aktienübersicht

Syneos Health, Inc., operates as an integrated biopharmaceutical solutions company. Mehr Details

SYNH grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	2/6
Künftiges Wachstum	3/6
Vergangene Leistung	1/6
Finanzielle Gesundheit	3/6
Dividenden	0/6

Belohnungen

25.3% unter unserer Schätzung des beizulegenden Zeitwerts gehandelt

Prognostiziertes Gewinnwachstum 33.7% pro Jahr

Risikoanalyse

Die Verschuldung ist durch den operativer Cashflow nicht gut gedeckt

Große einmalige Posten, die sich auf die Finanzergebnisse auswirken

Die Gewinnspannen (1.3%) sind niedriger als im Vorjahr (5.1%)

Syneos Health, Inc. Wettbewerber

Sotera Health

NasdaqGS:SHC

US$3.9b

Stevanato Group

NYSE:STVN

US$4.8b

Bruker

NasdaqGS:BRKR

US$7.5b

Charles River Laboratories International

NYSE:CRL

US$9.6b

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Syneos Health
Historische Aktienkurse
Aktueller Aktienkurs	US$42.98
52-Wochen-Hoch	US$52.23
52-Wochen-Tief	US$22.89
Beta	1.58
11 Monat Veränderung	0.66%
3 Monate Veränderung	1.99%
1 Jahr Veränderung	-8.84%
33 Jahre Veränderung	-23.06%
5 Jahre Veränderung	-10.61%
Veränderung seit IPO	109.76%

Aktuelle Nachrichten und Updates

Recent updates

Is There An Opportunity With Syneos Health, Inc.'s (NASDAQ:SYNH) 49% Undervaluation?

Jun 18

Is Now The Time To Look At Buying Syneos Health, Inc. (NASDAQ:SYNH)?

Jun 03

We Think Syneos Health (NASDAQ:SYNH) Can Stay On Top Of Its Debt

May 19

Do Syneos Health's (NASDAQ:SYNH) Earnings Warrant Your Attention?

Apr 08

Syneos Health: Upside Opportunity After Unexpected Correction In CRO Market, M&A Rumors

Mar 27

Is Now An Opportune Moment To Examine Syneos Health, Inc. (NASDAQ:SYNH)?

Mar 05

Is Syneos Health (NASDAQ:SYNH) A Risky Investment?

Feb 18

Are Investors Undervaluing Syneos Health, Inc. (NASDAQ:SYNH) By 39%?

Feb 03

With EPS Growth And More, Syneos Health (NASDAQ:SYNH) Is Interesting

Jan 04

Syneos Health's Double-Digit Revenue Growth Sets The Tone For A Strong 2022

Dec 03

Is It Too Late To Consider Buying Syneos Health, Inc. (NASDAQ:SYNH)?

Dec 03

Aktionärsrenditen

	SYNH	US Life Sciences	US Markt
7D	0.6%	-9.0%	-2.1%
1Y	-8.8%	2.9%	29.7%

Rendite im Vergleich zur Industrie: SYNH übertraf die Branche US Life Sciences , die im vergangenen Jahr eine Rendite von 2.9 erzielte.

Rendite vs. Markt: SYNH hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 29.7 erzielte.

Preisvolatilität

Is SYNH's price volatile compared to industry and market?
SYNH volatility
SYNH Average Weekly Movement	0.3%
Life Sciences Industry Average Movement	8.7%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.6%
10% least volatile stocks in US Market	3.1%

Stabiler Aktienkurs: SYNH hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.

Volatilität im Zeitverlauf: SYNHDie wöchentliche Volatilität der Aktie ist im vergangenen Jahr von 9% auf 0% zurückgegangen.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2010	28,768	Michelle Keefe	www.syneoshealth.com

Syneos Health, Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Syneos Health im Vergleich zum Marktanteil des Unternehmens?
SYNH grundlegende Statistiken
Marktanteil	US$4.46b
Gewinn(TTM)	US$71.22m
Umsatz(TTM)	US$5.42b

62.6x

Kurs-Gewinn-Verhältnis

0.8x

Kurs-Umsatz-Verhältnis

Ist SYNH zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
SYNH Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$5.42b
Kosten der Einnahmen	US$4.22b
Bruttogewinn	US$1.20b
Sonstige Ausgaben	US$1.13b
Umsatz	US$71.22m

Zuletzt gemeldete Gewinne

Jun 30, 2023

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	0.69
Bruttomarge	22.14%
Nettogewinnspanne	1.31%
Schulden/Eigenkapital-Verhältnis	75.8%

Wie hat sich SYNH auf lange Sicht entwickelt?

Historische Performance und Vergleiche

SYNH Aktienübersicht

Belohnungen

Risikoanalyse

Syneos Health, Inc. Wettbewerber

NasdaqGS:SHC

US$3.9b

NYSE:STVN

US$4.8b

NasdaqGS:BRKR

US$7.5b

NYSE:CRL

US$9.6b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Syneos Health, Inc. Announces Board Appointments

Syneos Health Files Form 15

Syneos Health, Inc. Announces Chief Executive Officer Changes

Syneos Health, Inc. Announces Management Changes

Patient Square Capital, LP, Elliott Investment Management L.P. and Veritas Capital Fund Management, L.L.C completed the acquisition of Syneos Health, Inc. (NasdaqGS:SYNH) from a group of shareholders.

Syneos Health Names Terttu Haring President, Clinical Sites & Patients

Recent updates

Syneos Health, Inc. Announces Board Appointments

Syneos Health Files Form 15

Syneos Health, Inc. Announces Chief Executive Officer Changes

Syneos Health, Inc. Announces Management Changes

Patient Square Capital, LP, Elliott Investment Management L.P. and Veritas Capital Fund Management, L.L.C completed the acquisition of Syneos Health, Inc. (NasdaqGS:SYNH) from a group of shareholders.

Syneos Health Names Terttu Haring President, Clinical Sites & Patients

Levi & Korsinsky Notifies Syneos Health, Inc. Investors of A Class Action Lawsuit and Upcoming Deadline

Consensus EPS estimates fall by 70%

The Klein Law Firm Announces That a Class Action Complaint Has Been Filed on Behalf of Shareholders of Syneos Health, Inc

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Syneos Health, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Syneos Health, Inc

Syneos Health Appoints Hillary Bochniak as Chief Human Resources Officer

Syneos Health, Inc. Appoints Batisha Anson to Global Head, Patient Diversity and Health Equity

Consensus EPS estimates fall from profit to US$0.31 loss, revenue upgraded

Patient Square Capital, LP, Elliott Investment Management L.P. and Veritas Capital Fund Management, L.L.C entered into an agreement to acquire Syneos Health, Inc. (NasdaqGS:SYNH) in a transaction valued at approximately $7.5 billion.

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improves as stock rises 17%

Is Now The Time To Look At Buying Syneos Health, Inc. (NASDAQ:SYNH)?

Does Syneos Health (NASDAQ:SYNH) Have A Healthy Balance Sheet?

Is Syneos Health, Inc. (NASDAQ:SYNH) Trading At A 40% Discount?

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Syneos Health, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Consensus EPS estimates fall by 11%

Price target decreased by 10% to US$36.95

Syneos Health, Inc. to Report Q4, 2022 Results on Feb 16, 2023

Syneos Health, Inc. Reaffirms Revenue Guidance for the Full Year 2022

Should You Investigate Syneos Health, Inc. (NASDAQ:SYNH) At US$34.33?

Is Syneos Health (NASDAQ:SYNH) Using Too Much Debt?

High number of new directors

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Syneos Health, Inc. Revises Earnings Guidance for the Fiscal Year 2022

Here's Why Syneos Health (NASDAQ:SYNH) Has Caught The Eye Of Investors

Syneos Health Adds Hub Patient Suite to Deployment Solutions Business

Syneos Health, Inc. to Report Q3, 2022 Results on Nov 04, 2022

Syneos Health, Inc. Announces Executive Changes

Price target decreased to US$69.73

Syneos, Datavant expand partnership on data analytics for clinical trials

Investor sentiment deteriorated over the past week

Syneos Health falls 13% after update on outlook

When Should You Buy Syneos Health, Inc. (NASDAQ:SYNH)?

Is Syneos Health (NASDAQ:SYNH) A Risky Investment?

Syneos Health, Inc. (NasdaqGS:SYNH) acquired Boco Digital Media, LLC.

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Syneos Health, Inc. Provides Earnings Guidance for the Third Quarter of 2022

Syneos Health Q2 2022 Earnings Preview

With EPS Growth And More, Syneos Health (NASDAQ:SYNH) Makes An Interesting Case

Syneos Health, Inc. to Report Q2, 2022 Results on Aug 02, 2022

Syneos: Upside Could Be Priced In, Valuations Unsupportive

Is There An Opportunity With Syneos Health, Inc.'s (NASDAQ:SYNH) 49% Undervaluation?

Is Now The Time To Look At Buying Syneos Health, Inc. (NASDAQ:SYNH)?

We Think Syneos Health (NASDAQ:SYNH) Can Stay On Top Of Its Debt

Consensus forecasts updated

High number of new directors

Syneos Health, Inc. Revises Earnings Guidance for the Fiscal Year 2022

First quarter 2022 earnings: EPS misses analyst expectations

Syneos Health Announces Executive Promotions

Syneos Health, Inc., Annual General Meeting, May 25, 2022

Erträge & Einnahmen